3,6,9,12,15,18,21,24,27,30-Decaoxahentriacontanoic acid

 CAS No.: 405518-55-0  Cat No.: BP-501685  Purity: 95% 4.5  

m-PEG9-CH2COOH is a polyethylene glycol (PEG)-based PROTAC linker. m-PEG9-CH2COOH can be used in the synthesis of a series of PROTACs.

3,6,9,12,15,18,21,24,27,30-Decaoxahentriacontanoic acid

Structure of 405518-55-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
PROTAC Linker
Molecular Formula
C21H42O12
Molecular Weight
486.55

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • mg to g scale for early stage;
  • CDMO and CMO support.
  • 24/7 customer service;
  • 100% quality assurance;
  • Efficient global delivery;
  • Over 95% customer satisfaction.
Popular Publications Citing BOC Sciences Products
Purity
95%
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid
Synonyms
3,6,9,12,15,18,21,24,27,30-DECAOXAHENTRIACONTANOICACID; 405518-55-0; 2,5,8,11,14,17,20,23,26,29-Decaoxahentriacontan-31-oicacid; SCHEMBL3541625; CTK1D4871; XVVLEAQJQOTYFV-UHFFFAOYSA-N
Boiling Point
557.372°C at 760 mmHg
Density
1.122
InChI Key
XVVLEAQJQOTYFV-UHFFFAOYSA-N
InChI
InChI=1S/C21H42O12/c1-24-2-3-25-4-5-26-6-7-27-8-9-28-10-11-29-12-13-30-14-15-31-16-17-32-18-19-33-20-21(22)23/h2-20H2,1H3,(H,22,23)
Canonical SMILES
COCCOCCOCCOCCOCCOCCOCCOCCOCCOCC(=O)O
1.Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid.
Mardas N1, Busetti J2, de Figueiredo JA3, Mezzomo LA4, Scarparo RK5, Donos N6. Clin Oral Implants Res. 2016 Feb 26. doi: 10.1111/clr.12810. [Epub ahead of print]
OBJECTIVES: To evaluate new bone formation in calvarial critical size defects (CSD) under dense polytetrafluoroethylene (d-PTFE), microporous membranes for guided bone regeneration (GBR) in healthy, osteoporotic and osteoporotic treated with zoledronic acid (ZA) rats.
2.Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).
Dhir V1, Sandhu A2, Kaur J3, Pinto B4, Kumar P5, Kaur P6, Gupta N7, Sood A8, Sharma A9, Sharma S10. Arthritis Res Ther. 2015 Jun 11;17:156. doi: 10.1186/s13075-015-0668-4.
INTRODUCTION: There is reasonable evidence that folic acid 5-10 mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this is based on studies conducted with lower MTX dosage than used currently. It is unclear whether higher doses of folic acid may be better in reducing toxicity.
3.[Chemical constituents from lipophilic parts in roots of Angelica dahurica var. formosana cv. Chuanbaizhi].
Deng GG, Yang XW, Zhang YB, Xu W, Wei W, Chen TL. Zhongguo Zhong Yao Za Zhi. 2015 Jun;40(11):2148-56.
The chemical constituents from lipophilic parts in the roots of Angelica dahurica var. formosana cv. Chuanbaizhi were studied in this paper. The compounds were separated and purified by repeated column chromatographic methods on silica gel and HPLC, and the chemical structures of compounds were determined by spectral data analyses. Twenty-nine compounds were obtained and identified as isoimperatorin (1), β-sitosterol (2), imperatorin (3), bergapten (4), osthenol (5), xanthotoxin (6), isoimpinellin (7), dehydrogeijerin (8), phellopterin (9), isodemethylfuropinarine (10), 7-demethylsuberosin (11), alloimperatorin (12), xanthotoxol (13), isooxypeucedanin (14), alloisoimperatorin (15), demethylfuropinarine (16), 5-hydroxy-8-methoxypsoralen (17), oxypeucedanin methanolate (18), pabulenol (19), byakangelicin (20), marmesin (21), (+) -decursinol (22), heraclenol (23), oxypeucedanin hydrate (24), marmesinin (25), ulopterol (26), erythro-guaiacylglycerol-β-ferulic acid ether (27), threo-guaiacylglycerol-β-ferulic acid ether (28), and uracil (29).
4.Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease.
Chen J1, Mohler ER2, Xie D3, Shlipak M4, Townsend RR2, Appel LJ5, Ojo A6, Schreiber M7, Nessel L3, Zhang X3, Raj D8, Strauss L9, Lora CM10, Rahman M9, Hamm LL11, He J1; CRIC Study Investigators. Nephrol Dial Transplant. 2015 Dec 18. pii: gfv418. [Epub ahead of print]
BACKGROUND: The risk of peripheral arterial disease (PAD) is higher in patients with chronic kidney disease (CKD) compared with those without. However, reasons for this increased risk are not fully understood.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket